Marshall Wace North America L.P. decreased its position in Henry Schein, Inc. (NASDAQ:HSIC) by 17.9% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 242,888 shares of the company’s stock after selling 52,887 shares during the period. Marshall Wace North America L.P. owned 0.31% of Henry Schein worth $44,448,000 as of its most recent filing with the SEC.

Several other large investors have also recently modified their holdings of HSIC. SpiderRock Advisors LLC purchased a new stake in shares of Henry Schein during the first quarter worth approximately $102,000. Lee Financial Co purchased a new stake in shares of Henry Schein during the second quarter worth approximately $161,000. Westside Investment Management Inc. purchased a new stake in shares of Henry Schein during the first quarter worth approximately $168,000. JNBA Financial Advisors purchased a new stake in shares of Henry Schein during the first quarter worth approximately $170,000. Finally, Peddock Capital Advisors LLC boosted its stake in shares of Henry Schein by 29.1% in the first quarter. Peddock Capital Advisors LLC now owns 1,097 shares of the company’s stock worth $186,000 after buying an additional 247 shares during the last quarter. 90.60% of the stock is currently owned by institutional investors and hedge funds.

Henry Schein, Inc. (NASDAQ HSIC) opened at 169.49 on Monday. Henry Schein, Inc. has a 12 month low of $146.23 and a 12 month high of $186.99. The stock’s 50 day moving average price is $179.49 and its 200-day moving average price is $175.49. The stock has a market cap of $13.40 billion, a price-to-earnings ratio of 24.77 and a beta of 1.09. Shares of Henry Schein are going to split on Friday, September 15th. The 2-1 split was announced on Wednesday, August 16th. The newly created shares will be issued to shareholders after the market closes on Thursday, September 14th.

Henry Schein (NASDAQ:HSIC) last issued its quarterly earnings data on Tuesday, August 8th. The company reported $1.75 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.73 by $0.02. Henry Schein had a return on equity of 19.91% and a net margin of 4.59%. The business had revenue of $3.06 billion for the quarter, compared to the consensus estimate of $3.05 billion. During the same period in the prior year, the business earned $1.64 earnings per share. The business’s revenue was up 6.4% on a year-over-year basis. Equities research analysts predict that Henry Schein, Inc. will post $7.27 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This story was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another domain, it was illegally copied and republished in violation of US and international copyright and trademark law. The legal version of this story can be accessed at https://www.thecerbatgem.com/2017/08/21/marshall-wace-north-america-l-p-has-44-45-million-stake-in-henry-schein-inc-hsic.html.

A number of brokerages have recently commented on HSIC. Credit Suisse Group reaffirmed a “hold” rating and set a $160.00 price objective on shares of Henry Schein in a research note on Thursday, July 13th. Barrington Research raised their price objective on shares of Henry Schein from $196.00 to $198.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 10th. Zacks Investment Research raised shares of Henry Schein from a “hold” rating to a “buy” rating and set a $204.00 price objective on the stock in a research note on Thursday, May 25th. Stifel Nicolaus raised their price objective on shares of Henry Schein from $174.00 to $178.00 and gave the stock a “hold” rating in a research note on Wednesday, May 10th. Finally, Piper Jaffray Companies began coverage on shares of Henry Schein in a research note on Monday, June 12th. They set a “neutral” rating and a $200.00 price objective on the stock. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating and seven have assigned a buy rating to the stock. Henry Schein currently has a consensus rating of “Hold” and a consensus price target of $185.56.

Henry Schein Company Profile

Henry Schein, Inc is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.

Want to see what other hedge funds are holding HSIC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Henry Schein, Inc. (NASDAQ:HSIC).

Institutional Ownership by Quarter for Henry Schein (NASDAQ:HSIC)

Receive News & Stock Ratings for Henry Schein Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein Inc. and related stocks with our FREE daily email newsletter.